RLFTF News and Press, Mondobiotech Holding AG Basel From 11/07/22

Relief Therapeutics ( OTCQB:RLFTF )( OTCQB:RLFTD ) reported six-month stability data on a new formulation of potential lung disease therapy RLF-100 (aviptadil). The company said the data showed high purity levels at six months at all temperatures tested, including a...

This new formulation may have important clinical uses for a variety of rare lung diseases GENEVA, SWITZERLAND / ACCESSWIRE / November 7, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTD) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying,...

GENEVA, SWITZERLAND / ACCESSWIRE / October 26, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), today announced that they and NRx Pharmaceuticals, Inc. ("NRx") have agreed to extend the stay of their pending litigation until November 7, 2022 to allow time...

Relief Therapeutics Files Amendment No. 2 to its Form F-6 Registration Statement with the U.S. Securities and Exchange Commission to Reverse Split and Change the Ratio of its ADRs to Ordinary Shares from 1 to 150 to 1 to 200 GENEVA, SWITZERLAND / ACCESSWIRE / October 25, 2022 / RELIEF T...

Relief Therapeutics ( OTCQB:RLFTF ) has announced that Paolo Galfetti has been promoted to Chief Operating Officer, effective October 14, 2022. Paolo will continue his responsibilities as CEO of APR Applied Pharma Research and as a member of Relief's Board of Directors. ...

GENEVA, SWITZERLAND / ACCESSWIRE / October 14, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-stage biopharmaceutical company identifying, developing and commercializing novel, patent protected products in selected specialty, rare an...

Relief Therapeutics ( OTCQB:RLFTF )( OTCQB:RLFTY ) said it launched medical food product PKU GOLIKE in the U.S. for the dietary management of phenylketonuria (PKU) PKU is a rare inherited disorder caused by a defect in an enzyme needed to break down an amino acid ...

First sale of PKU Golike ® in the U.S. through Relief's exclusive national distributor Relief will issue milestone payment and increase its share capital to create 200 million additional treasury shares GENEVA, SWITZERLAND / ACCESSWIRE / October 10, 2022 / RELIEF THERAPEUTICS...

Relief Therapeutics ( OTCQB:RLFTF ) has hired a leading provider of food for special medical purposes to help maximize patient access in support of PKU GOLIKE ® U.S. launch. PKU GOLIKE ® is a next generation medical food product engineered with the paten...

Leading Provider of Food for Special Medical Purposes to Help Maximize Patient Access in Support of PKU GOLIKE ® U.S. Launch GENEVA, SWITZERLAND / ACCESSWIRE / October 6, 2022 / RELIEF THERAPEUTICS Holding SA (SIX:RLF)(OTCQB:RLFTF)(OTCQB:RLFTY) ("Relief"), a Swiss, commercial-sta...